Back to Search Start Over

Intestinal transit amplifying cells require METTL3 for growth factor signaling, KRAS expression, and cell survival.

Authors :
Danan CH
Naughton KE
Hayer KE
Vellappan S
McMillan EA
Zhou Y
Matsuda R
Nettleford SK
Katada K
Parham LR
Ma X
Chowdhury A
Wilkins BJ
Shah P
Weitzman MD
Hamilton KE
Source :
BioRxiv : the preprint server for biology [bioRxiv] 2023 Apr 21. Date of Electronic Publication: 2023 Apr 21.
Publication Year :
2023

Abstract

Intestinal epithelial transit amplifying cells are essential stem progenitors required for intestinal homeostasis, but their rapid proliferation renders them vulnerable to DNA damage from radiation and chemotherapy. Despite their critical roles in intestinal homeostasis and disease, few studies have described genes that are essential to transit amplifying cell function. We report that the RNA methyltransferase, METTL3, is required for survival of transit amplifying cells in the murine small intestine. Transit amplifying cell death after METTL3 deletion was associated with crypt and villus atrophy, loss of absorptive enterocytes, and uniform wasting and death in METTL3-depleted mice. Ribosome profiling and sequencing of methylated RNAs in enteroids and in vivo demonstrated decreased translation of hundreds of unique methylated transcripts after METTL3 deletion, particularly transcripts involved in growth factor signal transduction such as Kras . Further investigation confirmed a novel relationship between METTL3 and Kras methylation and protein levels in vivo . Our study identifies METTL3 as an essential factor supporting the homeostasis of small intestinal tissue via direct maintenance of transit amplifying cell survival. We highlight the crucial role of RNA modifications in regulating growth factor signaling in the intestine, with important implications for both homeostatic tissue renewal and epithelial regeneration.<br />Competing Interests: Conflict-of-interest statement Premal Shah is a member of the Scientific Advisory Board of Trestle Biosciences and is Director at Ananke Therapeutics. All other authors declare they have no competing interests.

Details

Language :
English
ISSN :
2692-8205
Database :
MEDLINE
Journal :
BioRxiv : the preprint server for biology
Publication Type :
Academic Journal
Accession number :
37066277
Full Text :
https://doi.org/10.1101/2023.04.06.535853